- Policy
- Prior approval not required for reimb of Strensiq in KOR
- by Lee, Tak-Sun Apr 1, 2024 05:29am
- Strensiq Inj (asfotase alfa, AstraZeneca), which was subject to prior review by the Health Insurance Review and Assessment Service since it was listed for reimbursement in June 2020, will be converted and be subject to post-review from next month. The drug is a long-term enzyme replacement therapy used to treat bone symptoms in patients w
- Policy
- The NHI Trade Union says, 'NHIS should join the DREC'...
- by Lee, Tak-Sun Mar 29, 2024 05:53am
- The National Health Insurance Trade Union has criticized the government’s ‘The Second Comprehensive Plan of National Health Insurance’ regarding measures to strengthen patients’ access to new drugs. The union argued that the government formulated the policy referencing the corporate civil complaint. And added, it would be more effect
- Policy
- "Seek social consensus, shift away from 2,000 quota"
- by Lee, Jeong-Hwan Mar 29, 2024 05:53am
- "How can we persuade and negotiate with the medical community after President Yoon Suk Yeol forced university assignments by pushing through with an excessive fixation on increasing the quota to 2,000? It's time to shift away from this fixation and instead establish a committee proposed by the Democratic Party to facilitate social discussi
- Company
- AZ’s Sidapvia can be prescribed in general hospitals in KOR
- by Eo, Yun-Ho Mar 29, 2024 05:53am
- The diabetes combination drug Sidapvia can now be prescribed in general hospitals in Korea. According to industry sources, AstraZeneca Korea's Sidapvia (dapagliflozin-sitagliptin), which is a combination of its SGLT-2 inhibitor ‘Forxiga’ and DPP-4 inhibitor ‘Januvia’, has passed the drug committees(DCs) of around 30 medical institutio
- Company
- Reimb of renal anemia drug in progress upon FDA approval
- by Nho, Byung Chul Mar 29, 2024 05:53am
- The discussions on the insurance reimbursement of tablet-type renal anemia drugs are expected to gain momentum. As Korea’s health authorities were eyeing whether to start pricing negotiations for Mitsubishi Tanabe Pharma’s Vadanem based on the FDA’s approval decision in the U.S. and pricing decision in Europe, the FDA approval is expec
- Policy
- NHIS expands info disclosure about drug pricing negotiations
- by Lee, Tak-Sun Mar 29, 2024 05:53am
- Starting in April, the public will have expanded access to information regarding drug pricing negotiations. Information on the types of negotiations of drugs under review and the outcomes of agreements will be made open to the public. According to industry sources on the 28th, the National Health Insurance Service (NHIS), in agreement w
- Policy
- JW Pharmaceutical agrees on RSA renewal terms for Hemlibra
- by Lee, Tak-Sun Mar 29, 2024 05:53am
- JW Pharmaceutical has reportedly agreed to renew its risk-sharing agreement (RSA) for its hemophilia treatment ‘Hemlibra SC injection’ with the National Health Insurance Service. The company for the leukemia drug ‘Venclexta Tab,’ which was also in the process of negotiating the terms of RSA renewal, is expected to push for a tempora
- Company
- Samsung Bioepis makes 3rd investment in ADCs
- by Son, Hyung-Min Mar 28, 2024 05:52am
- Samsung Group, together with Samsung Bioepis, has made its third investment in companies discovering Antibody-Drug Conjugates (ADCs). Samsung Group plans to actively participate in new drug commercialization through acquiring the original technology as Samsung Biologics expands its CDMO facility for producing ADCs. Samsung Group announced on
- Company
- HK Inno.N speeds up clinical research on its NSCLC candidate
- by Nho, Byung Chul Mar 28, 2024 05:52am
- On the 27th, HK inno.N announced that it will present the non-clinical trial results of its next-generation allosteric EGFR-tyrosine kinase inhibitor ("EGFR-TKI") candidate through a poster presentation at the American Association for Cancer Research (AACR) Annual Meeting 2024 from April 5 to 10 in the United States. e AACR is one of the
- Company
- New breast cancer drug ‘Truqap’ soon to land in KOR
- by Eo, Yun-Ho Mar 28, 2024 05:52am
- The AKT inhibitor 'Truqap' is likely to enter the Korean market. According to industry sources, AstraZeneca Korea has submitted an application for Truqap (capivasertib), which is used in combination with 'Faslodex (fulvestrant),' approval to the Ministry of Food and Drug Safety (MFDS), and is under review. The approval is expected to be
